Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indonesia Pharma Outlook From IPMG Director Parulian Simanjuntak: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Indonesia is one of the least attractive pharma markets in Asia, with multinational companies facing major obstacles due to government restrictions and lack of transparency. Deficiencies in patent protection and a sizeable counterfeit industry make the situation even grimmer there. International Pharmaceutical Manufacturers' Group Executive Director Parulian Simanjuntak talked with PharmAsia News about the regulations that are putting a stranglehold on manufacturers in Indonesia and MNCs that might otherwise be thinking about entering Indonesia. IPMG, based in Jakarta, is the association for international pharmaceutical companies doing business in Indonesia.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts